Recombinant IGF-1/BP3 protects against intestinal injury in a neonatal mouse NEC model

Xiaocai Yan,Elizabeth Managlia,Galen Carey,Norman Barton,Xiao-Di Tan,Isabelle G. De Plaen
DOI: https://doi.org/10.1038/s41390-024-03069-8
IF: 3.953
2024-02-29
Pediatric Research
Abstract:Recombinant human IGF-1/binding protein-3 (rhIGF-1/BP3) is currently being tested in phase II clinical trials in premature infants to prevent bronchopulmonary dysplasia, but its impact on the neonatal intestine remains unclear. The aim of this study was to determine whether rhIGF-1/BP3 protects against necrotizing enterocolitis (NEC) in mice and to investigate the mechanisms involved.
pediatrics
What problem does this paper attempt to address?